What's new in breast cancer research?
7th October 2021
October is Breast Cancer Awareness Month and an important time of year to talk about the most common cancer. In 2020, breast cancer was the most diagnosed cancer worldwide with an estimated 2.3 million people affected. It’s also the fifth biggest cancer killer, responsible for an estimated 685,000 deaths worldwide in 2020.
In 2020, around 2.3 million people worldwide were diagnosed with breast cancer.
In 2020, around 685,000 people worldwide died from breast cancer.
Despite these numbers, thanks to research we have come a long way. Overall, breast cancer survival has improved dramatically. In the 1970s around 75% of people with cancer would survive 5 years or more after their diagnosis. Today that figure is over 90%.
But there are still hundreds of thousands of people dying from the disease each year. So, what do we need to do to find new cures for breast cancer? We asked three expert cancer researchers what they think is the most important area of breast cancer research that needs addressing right now.
Dr Greta Varchi, National Research Council, Italy:
“Breast cancer makes me think of Hydra, the gigantic mythical monster with nine heads. Each time a discovery seems to be the key to curing patients, new evidence indicates that we are still far from the solution.
“In the past decades, enormous progress has been made regarding early diagnosis and enhancing breast cancer patient care, leading to reduced morbidity and mortality. Nonetheless, several critical challenges remain.
“For example, conventional chemotherapy is almost ineffective against dormant cancer cells, which are responsible for the spread of cancer and the cause of death for so many. The development of resistance to systemic therapies also remains an unsolved issue. And triple-negative breast cancer, the most aggressive tumour subtype, is still lacking targeted therapies.
“In my opinion, one of the essential areas of research that still needs to be addressed and deepened is the development of concrete, personalized and targeted therapies able to simultaneously tackle primary tumour cells and dormant cancer cells while teaching the immune cells of the microenvironment, how to attack the tumour”.
Professor Neta Erez, Tel Aviv University, Israel:
“Mortality from breast cancer is almost exclusively a result of tumor metastasis – the spread of cancer to other organs. Since advanced metastatic cancers are incurable, understanding the biology of tumor metastasis is the most significant challenge in cancer research today.
“Metastasis is a complex multistep process. The early stages of metastasis, between the resection of primary tumor and diagnosis of clinically evident metastasis are currently a “black box” in patients, limiting our ability to predict or prevent metastatic relapse.
“Reaching a comprehensive understanding of the mechanisms underlying the early stages of the metastatic process is the most significant and urgent quest in cancer research today. This research is also essential for the discovery of novel therapeutic targets that aim to prevent metastatic relapse, rather than trying to treat advanced metastatic disease.”
Dr Manuel Valiente, CNIO, Spain:
“Cancers are not solely depending on cancer cells proliferating, but also on the tumour microenvironment. The microenvironment is the normal organ that in principle is doing its normal function. But when the cancer is there, these normal functions are changed so that the microenvironment is no longer serving the person, but serving the cancer. I think this is going to open a new area for developing therapies.”
Another exciting area of cancer research is one we are working on, and that is personalized therapies for cancer applied to metastasis. If you have a metastasis in the bone, we know that there is a survival mechanism that cancer cells need to colonise the bone. And that may be different to how these cells colonise the brain. So in the future, we are going to start seeing therapies that are applied according to where the metastasis is located. The hope is that by developing these new therapies we will be better able to fight cancer.”Find out more about Dr Manuel Valiente and his research
Like what you are reading? Sign up to our newsletter to get the latest cancer research breakthroughs, news and expert views delivered direct to your inbox.Sign up for our newsletter
Triple negative breast cancer (TNBC) is a particularly aggressive type of breast cancer for which more research is urgently needed. Here’s everything you need to know about TNBC.
01 October 2021
Breast cancer is one of the most common cancers in the world and although survival rates have improved dramatically over the years there is still so much more to do. Read about some of the recent discoveries our scientists have made.
12 October 2021
The experts give their views on hot topics in cancer: Rare cancers, stopping the spread of cancer, personalised medicine and immunotherapy.
03 September 2021